Last reviewed · How we verify
BMDex
BMDex is a dexamethasone-based treatment designed to enhance the efficacy of proteasome inhibitors and immunomodulatory drugs in multiple myeloma.
BMDex is a dexamethasone-based treatment designed to enhance the efficacy of proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Used for Multiple myeloma (in combination therapy).
At a glance
| Generic name | BMDex |
|---|---|
| Also known as | Bortezomid, Melphalan, Dexametasone |
| Sponsor | European Myeloma Network B.V. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BMDex combines dexamethasone with other anti-myeloma agents to improve treatment outcomes in multiple myeloma patients. The drug is being evaluated in phase 3 trials as part of combination therapy regimens for myeloma, leveraging dexamethasone's immunosuppressive and anti-inflammatory properties alongside other established myeloma therapeutics.
Approved indications
- Multiple myeloma (in combination therapy)
Common side effects
- Immunosuppression
- Hyperglycemia
- Infection risk
- Bone loss
Key clinical trials
- Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis (PHASE3)
- A Trial for Systemic Light-chain (AL) Amyloidosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |